Total Payments
$23,670
2024 Payments
$485.18
Companies
11
Transactions
203
Payment Breakdown by Category
Consulting$21,129 (89.3%)
Food & Beverage$2,020 (8.5%)
Research$485.18 (2.0%)
Education$28.99 (0.1%)
Travel$6.55 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $21,129 | 77 | 89.3% |
| Food and Beverage | $2,020 | 119 | 8.5% |
| Unspecified | $485.18 | 5 | 2.0% |
| Education | $28.99 | 1 | 0.1% |
| Travel and Lodging | $6.55 | 1 | 0.0% |
Payments by Type
General
$23,185
198 transactions
Research
$485.18
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $21,379 | 83 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $517.77 | 35 | $0 (2020) |
| SANOFI PASTEUR INC. | $485.18 | 5 | $0 (2024) |
| The Medicines Company | $368.49 | 32 | $0 (2017) |
| Melinta Therapeutics, Inc. | $326.38 | 19 | $0 (2019) |
| Astellas Pharma US Inc | $311.25 | 14 | $0 (2020) |
| Allergan Inc. | $83.85 | 5 | $0 (2019) |
| PFIZER INC. | $80.05 | 5 | $0 (2019) |
| TETRAPHASE PHARMACEUTICALS, INC. | $56.87 | 2 | $0 (2019) |
| Theravance Biopharma Inc. | $39.77 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $485.18 | 5 | SANOFI PASTEUR INC. ($485.18) |
| 2023 | $5,188 | 30 | Gilead Sciences, Inc. ($5,188) |
| 2022 | $6,545 | 24 | Gilead Sciences, Inc. ($6,545) |
| 2021 | $4,608 | 20 | Gilead Sciences, Inc. ($4,608) |
| 2020 | $5,080 | 11 | Gilead Sciences, Inc. ($5,038) |
| 2019 | $506.44 | 27 | Merck Sharp & Dohme Corporation ($194.06) |
| 2018 | $564.66 | 34 | Melinta Therapeutics, Inc. ($233.51) |
| 2017 | $692.84 | 52 | The Medicines Company ($368.49) |
All Payment Transactions
203 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $70.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/03/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $265.18 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 12/31/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $216.25 | General |
| 12/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 11/30/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 11/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 10/31/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 10/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 10/05/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $49.90 | General |
| 10/04/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $71.09 | General |
| 10/04/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $49.90 | General |
| 10/03/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $43.71 | General |
| 10/03/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.23 | General |
| 10/03/2023 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $6.55 | General |
| 09/30/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 09/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.53 | General |
| 08/31/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $202.01 | General |
| 08/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $203.74 | General |
| 07/31/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $212.75 | General |
| 07/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $212.75 | General |
| 06/30/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.96 | General |
| 06/15/2023 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $204.96 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | SANOFI PASTEUR INC. | $485.18 | 5 |
About Dr. Gloria Heresi, M.D
Dr. Gloria Heresi, M.D is a Pediatric Infectious Diseases healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689618050.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gloria Heresi, M.D has received a total of $23,670 in payments from pharmaceutical and medical device companies, with $485.18 received in 2024. These payments were reported across 203 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($21,129).
Ad
Practice Information
- Specialty Pediatric Infectious Diseases
- Other Specialties Pediatrics
- Location Houston, TX
- Active Since 06/16/2006
- Last Updated 08/08/2016
- Taxonomy Code 2080P0208X
- Entity Type Individual
- NPI Number 1689618050
Products in Payments
- MINOCIN IV (Drug) $264.46
- ZERBAXA (Drug) $208.49
- AMBISOME (Drug) $157.86
- NOXAFIL (Drug) $132.69
- ISENTRESS (Drug) $124.55
- PREVNAR - 13 (Biological) $80.05
- Orbactiv (Drug) $76.91
- MYCAMINE (Drug) $66.16
- Mycamine (Drug) $58.24
- AVYCAZ (Drug) $57.31
- ORBACTIV (Drug) $57.10
- Xerava (Drug) $56.87
- VABOMERE (Drug) $46.93
- VIBATIV (Drug) $39.77
- DIFICID (Drug) $29.63
- TEFLARO (Drug) $26.54
- NUZYRA (Drug) $21.52
- Vabomere (Drug) $15.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Infectious Diseases Doctors in Houston
Flor De Maria Munoz, Md, MD
Pediatric Infectious Diseases — Payments: $203,352
Pediatric Infectious Diseases $203,352
Dr. Rene Amaya, Md, MD
Pediatric Infectious Diseases — Payments: $84,107
Pediatric Infectious Diseases $84,107
Carol Baker, Md, MD
Pediatric Infectious Diseases — Payments: $42,942
Pediatric Infectious Diseases $42,942
Dr. Micah Bhatti, M.d., Phd, M.D., PHD
Pediatric Infectious Diseases — Payments: $30,056
Pediatric Infectious Diseases $30,056
Gail Demmler, Md, MD
Pediatric Infectious Diseases — Payments: $14,888
Pediatric Infectious Diseases $14,888
Sheldon Kaplan, Md, MD
Pediatric Infectious Diseases — Payments: $14,284
Pediatric Infectious Diseases $14,284